Ubs Asset Management Americas Inc Seres Therapeutics, Inc. Transaction History

Ubs Asset Management Americas Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$4.95 - $6.09 $58,073 - $71,447	11,732 Added 14.24%	94,095 $533,000
Q3 2022 Nov 14, 2022	SELL	$3.5 - $7.2 $61,981 - $127,504	-17,709 Reduced 17.7%	82,363 $528,000
Q2 2022 Aug 12, 2022	BUY	$2.7 - $7.62 $52,407 - $147,904	19,410 Added 24.06%	100,072 $343,000
Q1 2022 May 16, 2022	BUY	$6.3 - $8.84 $302 - $424	48 Added 0.06%	80,662 $574,000
Q4 2021 Feb 14, 2022	SELL	$6.02 - $11.43 $2.11 Million - $4 Million	-350,085 Reduced 81.28%	80,614 $671,000

Q3 2021 Nov 15, 2021	BUY	$5.46 - $22.6 $1.86 Million - $7.7 Million	340,635 Added 378.21%	430,699 $3 Million
Q2 2021 Aug 16, 2021	BUY	$18.46 - $24.36 $332,944 - $439,356	18,036 Added 25.04%	90,064 $2.15 Million
Q1 2021 May 14, 2021	BUY	$17.66 - $28.92 $158,834 - $260,106	8,994 Added 14.27%	72,028 $1.48 Million
Q4 2020 Mar 01, 2021	BUY	$23.25 - $37.73 $1.47 Million - $2.38 Million	63,034 New	63,034 $1.54 Million
Q2 2019 Aug 15, 2019	SELL	$2.28 - $7.35 $24,003 - $77,380	-10,528 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$4.83 - $7.21 $50,850 - $75,906	10,528 New	10,528 $0

100

62.7M

36.9K

476K

Ticker MCRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,072,000
Market Cap $89.3M
Description
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

Stay updated on Ubs Asset Management Americas Inc with notifications on news.